Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PARP9

Gene summary for PARP9

Gene summary.

Gene information	Species	Human
	Gene symbol	PARP9
	Gene ID	83666
	Gene name	poly(ADP-ribose) polymerase family member 9
	Gene Alias	ARTD9
	Cytomap	3q21.1
	Gene Type	protein-coding
	GO ID	GO:0000122
	UniProtAcc	Q8IXQ6

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
83666	PARP9	CA_HPV_1	Human	Cervix	CC	6.64e-06	2.89e-01	0.0264
83666	PARP9	CA_HPV_2	Human	Cervix	CC	1.87e-05	2.90e-01	0.0391
83666	PARP9	CCI_1	Human	Cervix	CC	1.68e-04	7.68e-01	0.528
83666	PARP9	CCI_2	Human	Cervix	CC	1.70e-08	1.04e+00	0.5249
83666	PARP9	CCI_3	Human	Cervix	CC	6.34e-16	1.41e+00	0.516
83666	PARP9	Tumor	Human	Cervix	CC	5.47e-31	6.60e-01	0.1241
83666	PARP9	sample3	Human	Cervix	CC	6.88e-36	6.68e-01	0.1387
83666	PARP9	T3	Human	Cervix	CC	9.19e-33	6.38e-01	0.1389
83666	PARP9	HTA11_1391_2000001011	Human	Colorectum	AD	1.71e-04	4.04e-01	-0.059
83666	PARP9	HTA11_99999970781_79442	Human	Colorectum	MSS	1.92e-21	8.15e-01	0.294
83666	PARP9	HTA11_99999965062_69753	Human	Colorectum	MSI-H	1.32e-04	1.06e+00	0.3487
83666	PARP9	LZE4T	Human	Esophagus	ESCC	1.65e-13	4.30e-01	0.0811
83666	PARP9	LZE5T	Human	Esophagus	ESCC	1.39e-03	2.56e-01	0.0514
83666	PARP9	LZE7T	Human	Esophagus	ESCC	4.74e-02	2.99e-01	0.0667
83666	PARP9	LZE8T	Human	Esophagus	ESCC	1.17e-06	3.53e-01	0.067
83666	PARP9	LZE20T	Human	Esophagus	ESCC	1.01e-05	2.70e-01	0.0662
83666	PARP9	LZE22T	Human	Esophagus	ESCC	1.85e-02	1.70e-01	0.068
83666	PARP9	LZE24T	Human	Esophagus	ESCC	3.65e-38	1.11e+00	0.0596
83666	PARP9	LZE21T	Human	Esophagus	ESCC	1.03e-02	2.47e-01	0.0655
83666	PARP9	P1T-E	Human	Esophagus	ESCC	8.35e-14	7.49e-01	0.0875

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001603210	Cervix	CC	viral process	109/2311	415/18723	5.40e-15	6.46e-12	109
GO:190382910	Cervix	CC	positive regulation of cellular protein localization	72/2311	276/18723	3.20e-10	4.46e-08	72
GO:00321035	Cervix	CC	positive regulation of response to external stimulus	95/2311	427/18723	5.44e-09	5.03e-07	95
GO:00345048	Cervix	CC	protein localization to nucleus	68/2311	290/18723	9.91e-08	5.25e-06	68
GO:005109810	Cervix	CC	regulation of binding	80/2311	363/18723	1.32e-07	6.42e-06	80
GO:00313494	Cervix	CC	positive regulation of defense response	60/2311	278/18723	9.38e-06	2.11e-04	60
GO:005109910	Cervix	CC	positive regulation of binding	42/2311	173/18723	1.07e-05	2.33e-04	42
GO:00028315	Cervix	CC	regulation of response to biotic stimulus	67/2311	327/18723	1.79e-05	3.36e-04	67
GO:00096158	Cervix	CC	response to virus	73/2311	367/18723	2.22e-05	3.95e-04	73
GO:20010209	Cervix	CC	regulation of response to DNA damage stimulus	46/2311	219/18723	1.92e-04	2.23e-03	46
GO:00192213	Cervix	CC	cytokine-mediated signaling pathway	84/2311	472/18723	3.25e-04	3.44e-03	84
GO:19001808	Cervix	CC	regulation of protein localization to nucleus	31/2311	136/18723	4.76e-04	4.69e-03	31
GO:00450882	Cervix	CC	regulation of innate immune response	44/2311	218/18723	6.40e-04	5.97e-03	44
GO:19001827	Cervix	CC	positive regulation of protein localization to nucleus	22/2311	87/18723	7.03e-04	6.40e-03	22
GO:00510528	Cervix	CC	regulation of DNA metabolic process	65/2311	359/18723	9.25e-04	7.84e-03	65
GO:00028331	Cervix	CC	positive regulation of response to biotic stimulus	35/2311	168/18723	1.23e-03	9.87e-03	35
GO:00343415	Cervix	CC	response to interferon-gamma	30/2311	141/18723	1.88e-03	1.39e-02	30
GO:00603333	Cervix	CC	interferon-gamma-mediated signaling pathway	9/2311	27/18723	3.82e-03	2.41e-02	9
GO:00713463	Cervix	CC	cellular response to interferon-gamma	25/2311	118/18723	4.54e-03	2.75e-02	25
GO:00190807	Cervix	CC	viral gene expression	21/2311	94/18723	4.68e-03	2.82e-02	21

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PARP9

SNV

Missense_Mutation

novel

c.914N>A

p.Thr305Asn

p.T305N

Q8IXQ6

protein_coding

deleterious(0.04)

possibly_damaging(0.598)

TCGA-AC-A5EH-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PARP9

SNV

Missense_Mutation

novel

c.1010N>A

p.Ser337Tyr

p.S337Y

Q8IXQ6

protein_coding

deleterious(0)

probably_damaging(0.995)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PARP9

SNV

Missense_Mutation

c.2293G>A

p.Glu765Lys

p.E765K

Q8IXQ6

protein_coding

deleterious(0)

possibly_damaging(0.53)

TCGA-AR-A0TX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

PARP9

SNV

Missense_Mutation

c.152N>T

p.Ser51Leu

p.S51L

Q8IXQ6

protein_coding

deleterious(0.01)

benign(0.049)

TCGA-BH-A0H7-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

doxorubicin

PARP9

SNV

Missense_Mutation

novel

c.615N>A

p.Asp205Glu

p.D205E

Q8IXQ6

protein_coding

tolerated(0.53)

benign(0.022)

TCGA-BH-A8FY-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PARP9

SNV

Missense_Mutation

c.170N>C

p.Gly57Ala

p.G57A

Q8IXQ6

protein_coding

tolerated(0.72)

benign(0.024)

TCGA-D8-A27G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PARP9

SNV

Missense_Mutation

c.1370A>C

p.His457Pro

p.H457P

Q8IXQ6

protein_coding

deleterious(0.01)

benign(0.015)

TCGA-E9-A1RF-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

tamoxiphen

PARP9

SNV

Missense_Mutation

novel

c.1903G>C

p.Asp635His

p.D635H

Q8IXQ6

protein_coding

tolerated(0.15)

possibly_damaging(0.751)

TCGA-EW-A3E8-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

anastrozole

PARP9

SNV

Missense_Mutation

c.1678N>T

p.Asp560Tyr

p.D560Y

Q8IXQ6

protein_coding

deleterious(0.03)

possibly_damaging(0.459)

TCGA-GM-A2DO-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

PARP9

insertion

Frame_Shift_Ins

novel

c.1041_1042insCAAAAAACAAACAAAACAACAA

p.Val348GlnfsTer19

p.V348Qfs*19

Q8IXQ6

protein_coding

TCGA-AO-A03T-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

Page: 1 2 3 4 5 6 7 8 9

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1